Identification

Name
Cabergoline
Accession Number
DB00248  (APRD00836)
Type
Small Molecule
Groups
Approved
Description

Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.

Structure
Thumb
Synonyms
  • (8beta)-N-[3-(dimethylamino)Propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
  • (8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
  • 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
  • 1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
  • 1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
  • Cabergolina
  • Cabergoline
  • Cabergolinum
External IDs
FCE 21336 / FCE-21336
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act CabergolineTablet0.5 mgOralActavis Pharma Company2007-11-06Not applicableCanada
CabergolineTablet.5 mg/1OralGreenstone, Llc2014-09-22Not applicableUs
CabergolineTablet0.5 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
DostinexTablet0.5 mgOralPfizer2000-06-30Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-cabergolineTablet0.5 mgOralApotex Corporation2017-03-23Not applicableCanada
CabergolineTablet.5 mg/1OralCobalt Laboratories2008-04-212017-01-13Us
CabergolineTablet.5 mg/1OralTeva2007-03-07Not applicableUs00093 5420 88 nlmimage10 8e2bc72e
CabergolineTablet.5 mg/1OralApotex Corporation2013-03-08Not applicableUs
CabergolineTablet.5 mg/1OralAvera Mc Kennan Hospital2015-04-14Not applicableUs
CabergolineTablet.5 mg/1OralMylan Pharmaceuticals2013-12-02Not applicableUs
CabergolineTablet.5 mg/1OralPar Pharmaceutical2005-12-29Not applicableUs
International/Other Brands
Cabaser (Pfizer)
Categories
UNII
LL60K9J05T
CAS number
81409-90-7
Weight
Average: 451.6043
Monoisotopic: 451.294725453
Chemical Formula
C26H37N5O2
InChI Key
KORNTPPJEAJQIU-KJXAQDMKSA-N
InChI
InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
IUPAC Name
1-[3-(dimethylamino)propyl]-3-ethyl-1-[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),9,12,14-tetraene-4-carbonyl]urea
SMILES
[H][[email protected]@]12CC3=CNC4=CC=CC(=C34)[[email protected]@]1([H])C[[email protected]](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC

Pharmacology

Indication

For the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas). May also be used to manage symptoms of Parkinsonian Syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease.

Structured Indications
Pharmacodynamics

Cabergoline stimulates centrally-located dopaminergic receptors resulting in a number of pharmacologic effects. Five dopamine receptor types from two dopaminergic subfamilies have been identified. The dopaminergic D1 receptor subfamily consists of D1 and D5 subreceptors, which are associated with dyskinesias. The dopaminergic D2 receptor subfamily consists of D2, D3 and D4 subreceptors, which are associated with improvement of symptoms of movement disorders. Thus, agonist activity specific for D2 subfamily receptors, primarily D2 and D3 receptor subtypes, are the primary targets of dopaminergic antiparkinsonian agents. It is thought that postsynaptic D2 stimulation is primarily responsible for the antiparkinsonian effect of dopamine agonists, while presynaptic D2 stimulation confers neuroprotective effects. This semisynthetic ergot derivative exhibits potent agonist activity on dopamine D2- and D3-receptors. It also exhibits: agonist activity (in order of decreasing binding affinities) on 5-hydroxytryptamine (5-HT)2B, 5-HT2A, 5-HT1D, dopamine D4, 5-HT1A, dopamine D1, 5-HT1B and 5-HT2C receptors and antagonist activity on α2B, α2A, and α2C receptors. Parkinsonian Syndrome manifests when approximately 80% of dopaminergic activity in the nigrostriatal pathway of the brain is lost. As this striatum is involved in modulating the intensity of coordinated muscle activity (e.g. movement, balance, walking), loss of activity may result in dystonia (acute muscle contraction), Parkinsonism (including symptoms of bradykinesia, tremor, rigidity, and flattened affect), akathesia (inner restlessness), tardive dyskinesia (involuntary muscle movements usually associated with long-term loss of dopaminergic activity), and neuroleptic malignant syndrome, which manifests when complete blockage of nigrostriatal dopamine occurs. High dopaminergic activity in the mesolimbic pathway of the brain causes hallucinations and delusions; these side effects of dopamine agonists are manifestations seen in patients with schizophrenia who have overractivity in this area of the brain. The hallucinogenic side effects of dopamine agonists may also be due to 5-HT2A agonism. The tuberoinfundibular pathway of the brain originates in the hypothalamus and terminates in the pituitary gland. In this pathway, dopamine inhibits lactotrophs in anterior pituitary from secreting prolactin. Increased dopaminergic activity in the tuberoinfundibular pathway inhibits prolactin secretion.

Mechanism of action

The dopamine D2 receptor is a 7-transmembrane G-protein coupled receptor associated with Gi proteins. In lactotrophs, stimulation of dopamine D2 causes inhibition of adenylyl cyclase, which decreases intracellular cAMP concentrations and blocks IP3-dependent release of Ca2+ from intracellular stores. Decreases in intracellular calcium levels may also be brought about via inhibition of calcium influx through voltage-gated calcium channels, rather than via inhibition of adenylyl cyclase. Additionally, receptor activation blocks phosphorylation of p42/p44 MAPK and decreases MAPK/ERK kinase phosphorylation. Inhibition of MAPK appears to be mediated by c-Raf and B-Raf-dependent inhibition of MAPK/ERK kinase. Dopamine-stimulated growth hormone release from the pituitary gland is mediated by a decrease in intracellular calcium influx through voltage-gated calcium channels rather than via adenylyl cyclase inhibition. Stimulation of dopamine D2 receptors in the nigrostriatal pathway leads to improvements in coordinated muscle activity in those with movement disorders. Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors. Receptor-binding studies indicate that cabergoline has low affinity for dopamine D1, α1,- and α2- adrenergic, and 5-HT1- and 5-HT2-serotonin receptors.

TargetActionsOrganism
AD(2) dopamine receptor
agonist
Human
U5-hydroxytryptamine receptor 2B
agonist
Human
UD(3) dopamine receptor
agonist
Human
U5-hydroxytryptamine receptor 2A
agonist
Human
UAlpha-2B adrenergic receptor
antagonist
Human
U5-hydroxytryptamine receptor 1D
agonist
Human
UD(4) dopamine receptor
agonist
Human
UAlpha-2A adrenergic receptor
antagonist
Human
U5-hydroxytryptamine receptor 1A
agonist
Human
UAlpha-2C adrenergic receptor
antagonist
Human
UD(1B) dopamine receptor
agonist
Human
UD(1A) dopamine receptor
agonist
Human
U5-hydroxytryptamine receptor 1B
agonist
Human
U5-hydroxytryptamine receptor 2C
agonist
Human
U5-hydroxytryptamine receptor 7
antagonist
Human
UAlpha-1A adrenergic receptor
binder
Human
UAlpha-1B adrenergic receptor
binder
Human
UAlpha-1D adrenergic receptor
binder
Human
UBeta-1 adrenergic receptor
binder
Human
UBeta-2 adrenergic receptor
binder
Human
UD(1) dopamine receptor
agonist
Human
UD(2S) dopamine receptor
agonist
Human
UD(2L) dopamine receptor
agonist
Human
Absorption

First-pass effect is seen, however the absolute bioavailability is unknown.

Volume of distribution
Not Available
Protein binding

Moderately bound (40% to 42%) to human plasma proteins in a concentration-independent manner.

Metabolism

Hepatic. Cabergoline is extensively metabolized, predominately via hydrolysis of the acylurea bond of the urea moiety. Cytochrome P-450 mediated metabolism appears to be minimal. The main metabolite identified in urine is 6-allyl-8b-carboxy-ergoline (4-6% of dose). Three other metabolites were identified urine (less than 3% of dose).

Route of elimination

After oral dosing of radioactive cabergoline to five healthy volunteers, approximately 22% and 60% of the dose was excreted within 20 days in the urine and feces, respectively. Less than 4% of the dose was excreted unchanged in the urine.

Half life

The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.

Clearance
  • renal cl=0,008 L/min
  • nonrenal cl=3.2 L/min
Toxicity

Overdosage might be expected to produce nasal congestion, syncope, or hallucinations.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Cabergoline can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Cabergoline can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Cabergoline can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe metabolism of Cabergoline can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcebutololAcebutolol may increase the vasoconstricting activities of Cabergoline.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Aceprometazine.Approved
AcetaminophenThe risk or severity of adverse effects can be increased when Cabergoline is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Acetophenazine.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Cabergoline.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Cabergoline.Experimental
AdrafinilCabergoline may increase the hypertensive activities of Adrafinil.Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Cabergoline is combined with Aldesleukin.Approved
AlmotriptanThe risk or severity of adverse effects can be increased when Cabergoline is combined with Almotriptan.Approved, Investigational
AlogliptinThe serum concentration of Cabergoline can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Cabergoline can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprazolamThe risk or severity of adverse effects can be increased when Cabergoline is combined with Alprazolam.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the vasoconstricting activities of Cabergoline.Approved, Withdrawn
AmbroxolThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ambroxol.Approved, Investigational
AmibegronCabergoline may increase the hypertensive activities of Amibegron.Investigational
AmiodaroneThe metabolism of Cabergoline can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Cabergoline.Approved, Investigational
AmitrazCabergoline may increase the hypertensive activities of Amitraz.Vet Approved
AmitriptylineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Amlodipine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Amperozide.Experimental
AmphetamineThe metabolism of Cabergoline can be decreased when combined with Amphetamine.Approved, Illicit
AmprenavirThe serum concentration of Cabergoline can be increased when it is combined with Amprenavir.Approved
AnastrozoleThe risk or severity of adverse effects can be increased when Cabergoline is combined with Anastrozole.Approved, Investigational
AnisodamineCabergoline may increase the hypertensive activities of Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Antipyrine.Approved
Antithrombin III humanThe serum concentration of Cabergoline can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Cabergoline can be increased when it is combined with Apixaban.Approved
ApomorphineCabergoline may increase the vasoconstricting activities of Apomorphine.Approved, Investigational
ApraclonidineCabergoline may increase the hypertensive activities of Apraclonidine.Approved
AprepitantThe serum concentration of Cabergoline can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Cabergoline can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineCabergoline may increase the hypertensive activities of Arbutamine.Approved
ArformoterolCabergoline may increase the hypertensive activities of Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Cabergoline can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Cabergoline is combined with Aripiprazole.Approved, Investigational
ArotinololArotinolol may increase the vasoconstricting activities of Cabergoline.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Arsenic trioxide.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Asenapine.Approved
AstemizoleThe risk or severity of adverse effects can be increased when Cabergoline is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Cabergoline can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe metabolism of Cabergoline can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the vasoconstricting activities of Cabergoline.Approved
AtomoxetineThe metabolism of Cabergoline can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Cabergoline is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Azaperone.Investigational, Vet Approved
AzelastineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Azelastine.Approved
AzithromycinThe risk or severity of adverse effects can be increased when Cabergoline is combined with Azithromycin.Approved
BatimastatThe serum concentration of Cabergoline can be increased when it is combined with Batimastat.Experimental
BefunololBefunolol may increase the vasoconstricting activities of Cabergoline.Experimental
BenazeprilThe serum concentration of Cabergoline can be increased when it is combined with Benazepril.Approved, Investigational
BenmoxinThe metabolism of Cabergoline can be decreased when combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Cabergoline is combined with Benperidol.Investigational
BenzamidineThe serum concentration of Cabergoline can be increased when it is combined with Benzamidine.Experimental
BetamethasoneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Betamethasone.Approved, Vet Approved
BetaxololBetaxolol may increase the vasoconstricting activities of Cabergoline.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Cabergoline.Approved, Investigational
BevantololBevantolol may increase the vasoconstricting activities of Cabergoline.Approved
BicalutamideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Bicalutamide.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Cabergoline is combined with Bifeprunox.Investigational
BifonazoleThe risk or severity of adverse effects can be increased when Cabergoline is combined with Bifonazole.Approved, Investigational
BisoprololBisoprolol may increase the vasoconstricting activities of Cabergoline.Approved
BitolterolCabergoline may increase the hypertensive activities of Bitolterol.Withdrawn
BivalirudinThe serum concentration of Cabergoline can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Cabergoline can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the vasoconstricting activities of Cabergoline.Approved
BortezomibThe metabolism of Cabergoline can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Cabergoline can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Cabergoline.Approved
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Cabergoline is combined with Brentuximab vedotin.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Cabergoline is combined with Brexpiprazole.Approved
BrimonidineCabergoline may increase the hypertensive activities of Brimonidine.Approved
BrofaromineThe metabolism of Cabergoline can be decreased when combined with Brofaromine.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Cabergoline is combined with Bromperidol.Investigational
BucindololBucindolol may increase the vasoconstricting activities of Cabergoline.Investigational
BufuralolBufuralol may increase the vasoconstricting activities of Cabergoline.Experimental, Investigational
BupranololBupranolol may increase the vasoconstricting activities of Cabergoline.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Cabergoline is combined with Buspirone.Approved, Investigational
ButaperazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Butaperazine.Experimental
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cabergoline.Approved
CaffeineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Caffeine.Approved
CamostatThe serum concentration of Cabergoline can be increased when it is combined with Camostat.Experimental
CandoxatrilThe serum concentration of Cabergoline can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Cabergoline can be increased when it is combined with Candoxatrilat.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Cabergoline is combined with Capsaicin.Approved
CaptoprilThe serum concentration of Cabergoline can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Cabergoline can be increased when combined with Carbamazepine.Approved, Investigational
CarbomycinThe serum concentration of Cabergoline can be increased when it is combined with Carbomycin.Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Cariprazine.Approved
CaroxazoneThe metabolism of Cabergoline can be decreased when combined with Caroxazone.Withdrawn
CarteololCarteolol may increase the vasoconstricting activities of Cabergoline.Approved
CarvedilolCarvedilol may increase the vasoconstricting activities of Cabergoline.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Cabergoline is combined with Caspofungin.Approved
CeliprololCeliprolol may increase the vasoconstricting activities of Cabergoline.Approved, Investigational
CeritinibThe serum concentration of Cabergoline can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Cabergoline.Withdrawn
ChloramphenicolThe risk or severity of adverse effects can be increased when Cabergoline is combined with Chloramphenicol.Approved, Vet Approved
ChlorproethazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Chlorzoxazone.Approved
CholesterolThe serum concentration of Cabergoline can be increased when it is combined with Cholesterol.Experimental, Investigational
ChymostatinThe serum concentration of Cabergoline can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Cabergoline can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Cabergoline can be increased when it is combined with Cilazapril.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cabergoline is combined with Cilostazol.Approved
CiprofloxacinThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ciprofloxacin.Approved, Investigational
CirazolineCabergoline may increase the hypertensive activities of Cirazoline.Experimental
CisaprideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Cisapride.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Cabergoline.Approved
ClarithromycinThe serum concentration of Cabergoline can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Cabergoline can be decreased when combined with Clemastine.Approved
ClenbuterolCabergoline may increase the hypertensive activities of Clenbuterol.Approved, Investigational, Vet Approved
ClindamycinThe risk or severity of adverse effects can be increased when Cabergoline is combined with Clindamycin.Approved, Vet Approved
ClofazimineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Clofazimine.Approved, Investigational
ClomifeneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Clomifene.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Clomipramine.Approved, Vet Approved
ClonidineCabergoline may increase the hypertensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Cabergoline is combined with Clopenthixol.Experimental
CloranololCloranolol may increase the vasoconstricting activities of Cabergoline.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Cabergoline is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe metabolism of Cabergoline can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Clozapine.Approved
CobicistatThe metabolism of Cabergoline can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Cocaine.Approved, Illicit
ColchicineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Colchicine.Approved
ConivaptanThe serum concentration of Cabergoline can be increased when it is combined with Conivaptan.Approved, Investigational
Cortisone acetateThe risk or severity of adverse effects can be increased when Cabergoline is combined with Cortisone acetate.Approved
CrizotinibThe metabolism of Cabergoline can be decreased when combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Cyamemazine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Cyclobenzaprine.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Cabergoline.Approved, Investigational
CyclosporineThe metabolism of Cabergoline can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Cabergoline.Experimental
Dabigatran etexilateThe serum concentration of Cabergoline can be increased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Cabergoline can be decreased when it is combined with Dabrafenib.Approved
DalfopristinThe risk or severity of adverse effects can be increased when Cabergoline is combined with Dalfopristin.Approved
DanazolThe risk or severity of adverse effects can be increased when Cabergoline is combined with Danazol.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Cabergoline is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Cabergoline.Investigational
DarexabanThe serum concentration of Cabergoline can be increased when it is combined with Darexaban.Investigational
DarunavirThe metabolism of Cabergoline can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Cabergoline can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Cabergoline is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Cabergoline can be decreased when it is combined with Deferasirox.Approved, Investigational
DelanzomibThe serum concentration of Cabergoline can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Cabergoline can be increased when it is combined with Delapril.Experimental
DelavirdineThe metabolism of Cabergoline can be decreased when combined with Delavirdine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Cabergoline.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Desvenlafaxine.Approved
DetomidineCabergoline may increase the hypertensive activities of Detomidine.Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineCabergoline may increase the hypertensive activities of Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Cabergoline is combined with Dextromethorphan.Approved
DextropropoxypheneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DiazepamThe risk or severity of adverse effects can be increased when Cabergoline is combined with Diazepam.Approved, Illicit, Vet Approved
DiethylstilbestrolThe risk or severity of adverse effects can be increased when Cabergoline is combined with Diethylstilbestrol.Approved, Investigational
DigitoxinDigitoxin may decrease the cardiotoxic activities of Cabergoline.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Cabergoline.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cabergoline.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Cabergoline.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Cabergoline.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Cabergoline.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Cabergoline can be decreased when combined with Diltiazem.Approved
Dimethyl sulfoxideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Dimethyl sulfoxide.Approved, Vet Approved
DipivefrinCabergoline may increase the hypertensive activities of Dipivefrin.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Dixyrazine.Experimental
DobutamineCabergoline may increase the hypertensive activities of Dobutamine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cabergoline.Approved, Investigational
DolasetronDolasetron may increase the serotonergic activities of Cabergoline.Approved
DopexamineCabergoline may increase the hypertensive activities of Dopexamine.Investigational
DoxepinThe risk or severity of adverse effects can be increased when Cabergoline is combined with Doxepin.Approved
DoxorubicinThe risk or severity of adverse effects can be increased when Cabergoline is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Cabergoline can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Cabergoline can be decreased when combined with Dronedarone.Approved
DroperidolThe risk or severity of adverse effects can be increased when Cabergoline is combined with Droperidol.Approved, Vet Approved
DroxidopaCabergoline may increase the hypertensive activities of Droxidopa.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Duloxetine.Approved
EcabetThe serum concentration of Cabergoline can be increased when it is combined with Ecabet.Approved, Investigational
EconazoleThe risk or severity of adverse effects can be increased when Cabergoline is combined with Econazole.Approved
EcopipamThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Cabergoline can be increased when it is combined with Edoxaban.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Cabergoline is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Cabergoline can be increased when it is combined with Elafin.Investigational
ElbasvirThe risk or severity of adverse effects can be increased when Cabergoline is combined with Elbasvir.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Cabergoline.Approved, Investigational
EnalaprilThe serum concentration of Cabergoline can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Cabergoline can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Cabergoline can be increased when it is combined with Enalkiren.Experimental
EnasidenibThe risk or severity of adverse effects can be increased when Cabergoline is combined with Enasidenib.Approved
EnzalutamideThe serum concentration of Cabergoline can be decreased when it is combined with Enzalutamide.Approved
EpanololEpanolol may increase the vasoconstricting activities of Cabergoline.Experimental
EphedrineCabergoline may increase the hypertensive activities of Ephedrine.Approved
Epigallocatechin GallateThe serum concentration of Cabergoline can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinastineCabergoline may increase the hypertensive activities of Epinastine.Approved, Investigational
EpinephrineCabergoline may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Cabergoline can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Cabergoline is combined with Escitalopram.Approved, Investigational
EsmololEsmolol may increase the vasoconstricting activities of Cabergoline.Approved
EthanolThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ethanol.Approved
EtilefrineCabergoline may increase the hypertensive activities of Etilefrine.Withdrawn
EtoposideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Etoposide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Cabergoline is combined with Etoricoxib.Approved, Investigational
EzetimibeThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ezetimibe.Approved
FaldaprevirThe serum concentration of Cabergoline can be increased when it is combined with Faldaprevir.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoterolCabergoline may increase the hypertensive activities of Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FluanisoneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Cabergoline can be decreased when combined with Fluconazole.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Cabergoline is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fluphenazine.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Cabergoline.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Cabergoline.Approved, Investigational
FormoterolCabergoline may increase the hypertensive activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Cabergoline can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Cabergoline can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Cabergoline can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Cabergoline can be increased when combined with Fosphenytoin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Cabergoline is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe metabolism of Cabergoline can be decreased when combined with Furazolidone.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Cabergoline can be increased when it is combined with Fusidic Acid.Approved
GabexateThe serum concentration of Cabergoline can be increased when it is combined with Gabexate.Investigational
GeldanamycinThe serum concentration of Cabergoline can be increased when it is combined with Geldanamycin.Experimental, Investigational
GemfibrozilThe risk or severity of adverse effects can be increased when Cabergoline is combined with Gemfibrozil.Approved
GitoformateGitoformate may decrease the cardiotoxic activities of Cabergoline.Experimental
GlyburideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Glyburide.Approved
Glycerol PhenylbutyrateThe risk or severity of adverse effects can be increased when Cabergoline is combined with Glycerol Phenylbutyrate.Approved
GM6001The serum concentration of Cabergoline can be increased when it is combined with GM6001.Experimental
GranisetronGranisetron may increase the serotonergic activities of Cabergoline.Approved, Investigational
GuanabenzCabergoline may increase the hypertensive activities of Guanabenz.Approved, Investigational
GuanfacineCabergoline may increase the hypertensive activities of Guanfacine.Approved, Investigational
HaloperidolThe risk or severity of adverse effects can be increased when Cabergoline is combined with Haloperidol.Approved
HarmalineThe metabolism of Cabergoline can be decreased when combined with Harmaline.Experimental
HexoprenalineCabergoline may increase the hypertensive activities of Hexoprenaline.Approved, Withdrawn
HigenamineCabergoline may increase the hypertensive activities of Higenamine.Investigational
HistamineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Histamine.Approved, Investigational
HydracarbazineThe metabolism of Cabergoline can be decreased when combined with Hydracarbazine.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Hydralazine.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Hydrocortisone.Approved, Vet Approved
IdraparinuxThe serum concentration of Cabergoline can be increased when it is combined with Idraparinux.Investigational
IfosfamideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ifosfamide.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Iloperidone.Approved
ImatinibThe metabolism of Cabergoline can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Cabergoline can be increased when it is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Imipramine.Approved
IndenololIndenolol may increase the vasoconstricting activities of Cabergoline.Withdrawn
IndinavirThe metabolism of Cabergoline can be decreased when combined with Indinavir.Approved
indisulamThe risk or severity of adverse effects can be increased when Cabergoline is combined with indisulam.Investigational
IproclozideThe metabolism of Cabergoline can be decreased when combined with Iproclozide.Withdrawn
IproniazidThe metabolism of Cabergoline can be decreased when combined with Iproniazid.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Cabergoline is combined with Irbesartan.Approved, Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Cabergoline is combined with Irinotecan.Approved, Investigational
IsavuconazoniumThe metabolism of Cabergoline can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Cabergoline is combined with Isocarboxazid.Approved
IsoetarineCabergoline may increase the hypertensive activities of Isoetarine.Approved
IsoflurophateThe serum concentration of Cabergoline can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe risk or severity of adverse effects can be increased when Cabergoline is combined with Isoniazid.Approved
IsoprenalineCabergoline may increase the hypertensive activities of Isoprenaline.Approved
IsoxsuprineCabergoline may increase the hypertensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Cabergoline can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Cabergoline can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Cabergoline can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Cabergoline can be increased when it is combined with Ixazomib.Approved
JosamycinThe serum concentration of Cabergoline can be increased when it is combined with Josamycin.Approved, Investigational
KetazolamThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ketazolam.Approved
KetoconazoleThe metabolism of Cabergoline can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Cabergoline can be increased when it is combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the vasoconstricting activities of Cabergoline.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Cabergoline.Experimental
LandiololLandiolol may increase the vasoconstricting activities of Cabergoline.Investigational
LansoprazoleThe risk or severity of adverse effects can be increased when Cabergoline is combined with Lansoprazole.Approved, Investigational
LapatinibThe risk or severity of adverse effects can be increased when Cabergoline is combined with Lapatinib.Approved, Investigational
LepirudinThe serum concentration of Cabergoline can be increased when it is combined with Lepirudin.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Lercanidipine.Approved, Investigational
LetaxabanThe serum concentration of Cabergoline can be increased when it is combined with Letaxaban.Investigational
LevobunololLevobunolol may increase the vasoconstricting activities of Cabergoline.Approved
LevofloxacinThe risk or severity of adverse effects can be increased when Cabergoline is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Cabergoline is combined with Levomilnacipran.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Cabergoline is combined with Levosalbutamol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Cabergoline can be increased when it is combined with Linagliptin.Approved
LinezolidThe risk or severity of adverse effects can be increased when Cabergoline is combined with Linezolid.Approved, Investigational
LisinoprilThe serum concentration of Cabergoline can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideCabergoline may increase the vasoconstricting activities of Lisuride.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Cabergoline is combined with Lithium.Approved
LofexidineCabergoline may increase the hypertensive activities of Lofexidine.Approved, Investigational
LomitapideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Lomitapide.Approved
LomustineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Lomustine.Approved
LopinavirThe metabolism of Cabergoline can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Loratadine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Cabergoline.Approved
LosartanThe risk or severity of adverse effects can be increased when Cabergoline is combined with Losartan.Approved
LovastatinThe metabolism of Cabergoline can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Cabergoline can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Cabergoline can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Lurasidone.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Cabergoline.Illicit, Investigational, Withdrawn
ManidipineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Maprotiline.Approved
MebanazineThe metabolism of Cabergoline can be decreased when combined with Mebanazine.Withdrawn
MedetomidineCabergoline may increase the hypertensive activities of Medetomidine.Vet Approved
MefloquineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Mefloquine.Approved
MelagatranThe serum concentration of Cabergoline can be increased when it is combined with Melagatran.Experimental
MelperoneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Melperone.Approved, Investigational
MephentermineCabergoline may increase the hypertensive activities of Mephentermine.Approved
MepindololMepindolol may increase the vasoconstricting activities of Cabergoline.Experimental
MequitazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Mesoridazine.Approved, Investigational
MetaraminolCabergoline may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Cabergoline.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Methazolamide.Approved
MethimazoleThe risk or severity of adverse effects can be increased when Cabergoline is combined with Methimazole.Approved
MethotrimeprazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Methotrimeprazine.Approved
MethoxamineCabergoline may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineCabergoline may increase the hypertensive activities of Methoxyphenamine.Experimental
MethyldopaCabergoline may increase the hypertensive activities of Methyldopa.Approved
Methylene blueThe metabolism of Cabergoline can be decreased when combined with Methylene blue.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Cabergoline.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Methylprednisolone.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Cabergoline.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Cabergoline.Experimental
MetipranololMetipranolol may increase the vasoconstricting activities of Cabergoline.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Metoclopramide.Approved, Investigational
MetoprololMetoprolol may increase the vasoconstricting activities of Cabergoline.Approved, Investigational
MetronidazoleThe risk or severity of adverse effects can be increased when Cabergoline is combined with Metronidazole.Approved
MetyraponeThe risk or severity of adverse effects can be increased when Cabergoline is combined with Metyrapone.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Cabergoline.Experimental
MibefradilThe risk or severity of adverse effects can be increased when Cabergoline is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe risk or severity of adverse effects can be increased when Cabergoline is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Cabergoline is combined with Midazolam.Approved, Illicit
MidodrineCabergoline may increase the hypertensive activities of Midodrine.Approved
MifepristoneThe serum concentration of Cabergoline can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Cabergoline is combined with Milnacipran.Approved
MinaprineThe metabolism of Cabergoline can be decreased when combined with Minaprine.Approved
MirabegronCabergoline may increase the hypertensive activities of Mirabegron.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Mirtazapine.Approved
MitotaneThe serum concentration of Cabergoline can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Moclobemide.Approved
ModafinilThe risk or severity of adverse effects can be increased when Cabergoline is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Cabergoline can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Moperone.Experimental
MosapramineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Mosapramine.Experimental
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Cabergoline can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NadololNadolol may increase the vasoconstricting activities of Cabergoline.Approved
NafamostatThe serum concentration of Cabergoline can be increased when it is combined with Nafamostat.Approved, Investigational
NaphazolineCabergoline may increase the hypertensive activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Cabergoline is combined with Naratriptan.Approved, Investigational
NebivololNebivolol may increase the vasoconstricting activities of Cabergoline.Approved, Investigational
NefazodoneThe metabolism of Cabergoline can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Cabergoline can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Cabergoline can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Cabergoline can be increased when combined with Nevirapine.Approved
NialamideThe metabolism of Cabergoline can be decreased when combined with Nialamide.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Cabergoline.Approved, Investigational
NicotinamideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Nicotinamide.Approved
NifedipineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Nifedipine.Approved
NilotinibThe metabolism of Cabergoline can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Nilvadipine.Approved, Investigational
NisoldipineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Nitric Oxide.Approved
NitroaspirinThe serum concentration of Cabergoline can be increased when it is combined with Nitroaspirin.Investigational
NitroglycerinCabergoline may decrease the vasodilatory activities of Nitroglycerin.Approved, Investigational
NorepinephrineCabergoline may increase the hypertensive activities of Norepinephrine.Approved
NorfenefrineCabergoline may increase the hypertensive activities of Norfenefrine.Experimental
NorfloxacinThe risk or severity of adverse effects can be increased when Cabergoline is combined with Norfloxacin.Approved
NortriptylineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Nortriptyline.Approved
NoscapineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Noscapine.Investigational
NylidrinCabergoline may increase the hypertensive activities of Nylidrin.Approved
OctamoxinThe metabolism of Cabergoline can be decreased when combined with Octamoxin.Withdrawn
OctopamineCabergoline may increase the hypertensive activities of Octopamine.Experimental
OlanzapineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Cabergoline can be decreased when combined with Olaparib.Approved
OleandomycinThe serum concentration of Cabergoline can be increased when it is combined with Oleandomycin.Vet Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Cabergoline.Experimental, Investigational
OlodaterolCabergoline may increase the hypertensive activities of Olodaterol.Approved
OmapatrilatThe serum concentration of Cabergoline can be increased when it is combined with Omapatrilat.Investigational
OmeprazoleThe risk or severity of adverse effects can be increased when Cabergoline is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the serotonergic activities of Cabergoline.Approved
OrciprenalineCabergoline may increase the hypertensive activities of Orciprenaline.Approved
OsanetantThe risk or severity of adverse effects can be increased when Cabergoline is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Cabergoline can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Cabergoline can be increased when it is combined with Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Cabergoline.Approved
OxprenololOxprenolol may increase the vasoconstricting activities of Cabergoline.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Cabergoline is combined with Oxybutynin.Approved, Investigational
OxyfedrineCabergoline may increase the hypertensive activities of Oxyfedrine.Experimental
OxymetazolineCabergoline may increase the hypertensive activities of Oxymetazoline.Approved
OxymetholoneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Oxymetholone.Approved, Illicit
OxypertineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Oxypertine.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cabergoline.Approved, Vet Approved
PalbociclibThe serum concentration of Cabergoline can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Cabergoline.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Paramethasone.Approved
PargylineThe metabolism of Cabergoline can be decreased when combined with Pargyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Paroxetine.Approved, Investigational
PazopanibThe risk or severity of adverse effects can be increased when Cabergoline is combined with Pazopanib.Approved
PenbutololPenbutolol may increase the vasoconstricting activities of Cabergoline.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Cabergoline is combined with Penfluridol.Experimental
PentobarbitalThe metabolism of Cabergoline can be increased when combined with Pentobarbital.Approved, Vet Approved
PerazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Perazine.Investigational
PergolideCabergoline may increase the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Cabergoline can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Cabergoline is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Perphenazine.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Cabergoline.Experimental
PethidineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Pethidine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Phenelzine.Approved
PheniprazineThe metabolism of Cabergoline can be decreased when combined with Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Cabergoline can be increased when combined with Phenobarbital.Approved
PhenoxypropazineThe metabolism of Cabergoline can be decreased when combined with Phenoxypropazine.Withdrawn
PhenylephrineCabergoline may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineCabergoline may increase the hypertensive activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Cabergoline can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Cabergoline can be increased when it is combined with Phosphoramidon.Experimental
PiclozotanCabergoline may increase the vasoconstricting activities of Piclozotan.Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Pilocarpine.Approved
PimozideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Pimozide.Approved
PindololPindolol may increase the vasoconstricting activities of Cabergoline.Approved
PipamperoneThe therapeutic efficacy of Pipamperone can be decreased when used in combination with Cabergoline.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Pipotiazine.Approved, Investigational
PirbuterolCabergoline may increase the hypertensive activities of Pirbuterol.Approved
PirlindoleThe metabolism of Cabergoline can be decreased when combined with Pirlindole.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Cabergoline.Approved
PivhydrazineThe metabolism of Cabergoline can be decreased when combined with Pivhydrazine.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the vasoconstricting activities of Cabergoline.Experimental
PosaconazoleThe metabolism of Cabergoline can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the vasoconstricting activities of Cabergoline.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Cabergoline.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Prednisone.Approved, Vet Approved
PrenalterolCabergoline may increase the hypertensive activities of Prenalterol.Experimental
PrimaquineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Primaquine.Approved
PrimidoneThe metabolism of Cabergoline can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Cabergoline can be increased when it is combined with Prinomastat.Investigational
ProcarbazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Procarbazine.Approved
ProcaterolCabergoline may increase the hypertensive activities of Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Prochlorperazine.Approved, Vet Approved
ProgesteroneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Progesterone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Promethazine.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Propericiazine.Approved
PropofolThe risk or severity of adverse effects can be increased when Cabergoline is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the vasoconstricting activities of Cabergoline.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Cabergoline.Experimental
ProthipendylThe risk or severity of adverse effects can be increased when Cabergoline is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Protriptyline.Approved
PRX-00023Cabergoline may increase the vasoconstricting activities of PRX-00023.Investigational
PseudoephedrineCabergoline may increase the hypertensive activities of Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Quetiapine.Approved
QuinaprilThe serum concentration of Cabergoline can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Quinidine.Approved
QuinineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Quinine.Approved
QuinupristinThe risk or severity of adverse effects can be increased when Cabergoline is combined with Quinupristin.Approved
RabeprazoleThe risk or severity of adverse effects can be increased when Cabergoline is combined with Rabeprazole.Approved, Investigational
RacecadotrilThe serum concentration of Cabergoline can be increased when it is combined with Racecadotril.Investigational
RacepinephrineCabergoline may increase the hypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Raclopride.Investigational
RactopamineCabergoline may increase the hypertensive activities of Ractopamine.Vet Approved
RaloxifeneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Raloxifene.Approved, Investigational
RamiprilThe serum concentration of Cabergoline can be increased when it is combined with Ramipril.Approved
RanitidineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ranitidine.Approved
RanolazineThe metabolism of Cabergoline can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Rasagiline.Approved
RegorafenibThe risk or severity of adverse effects can be increased when Cabergoline is combined with Regorafenib.Approved
RemikirenThe serum concentration of Cabergoline can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Remoxipride.Approved, Withdrawn
RepaglinideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Repaglinide.Approved, Investigational
ReproterolCabergoline may increase the hypertensive activities of Reproterol.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Reserpine.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Cabergoline is combined with Resveratrol.Approved, Experimental, Investigational
RifabutinThe metabolism of Cabergoline can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Cabergoline can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Cabergoline can be increased when combined with Rifapentine.Approved
RilmenidineCabergoline may increase the hypertensive activities of Rilmenidine.Investigational
RilpivirineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Rilpivirine.Approved
RimiterolCabergoline may increase the hypertensive activities of Rimiterol.Experimental
RisperidoneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ritanserin.Investigational
RitobegronCabergoline may increase the hypertensive activities of Ritobegron.Investigational
RitodrineCabergoline may increase the hypertensive activities of Ritodrine.Approved, Investigational
RitonavirThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Cabergoline can be increased when it is combined with Rivaroxaban.Approved
RivastigmineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Rivastigmine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Cabergoline is combined with Rizatriptan.Approved
RolitetracyclineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Rolitetracycline.Approved
RomifidineCabergoline may increase the hypertensive activities of Romifidine.Vet Approved
RopiniroleCabergoline may increase the vasoconstricting activities of Ropinirole.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Cabergoline.Approved
RoxithromycinThe serum concentration of Cabergoline can be increased when it is combined with Roxithromycin.Approved, Investigational, Withdrawn
RucaparibThe risk or severity of adverse effects can be increased when Cabergoline is combined with Rucaparib.Approved, Investigational
RutinThe risk or severity of adverse effects can be increased when Cabergoline is combined with Rutin.Experimental, Investigational
S-3304The serum concentration of Cabergoline can be increased when it is combined with S-3304.Investigational
SafrazineThe metabolism of Cabergoline can be decreased when combined with Safrazine.Withdrawn
SalbutamolCabergoline may increase the hypertensive activities of Salbutamol.Approved, Vet Approved
SalmeterolCabergoline may increase the hypertensive activities of Salmeterol.Approved
SaquinavirThe metabolism of Cabergoline can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe risk or severity of adverse effects can be increased when Cabergoline is combined with Sarilumab.Approved
SaxagliptinThe serum concentration of Cabergoline can be increased when it is combined with Saxagliptin.Approved
SelegilineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Cabergoline is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Sertraline.Approved
SildenafilThe metabolism of Cabergoline can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Cabergoline can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Cabergoline can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Cabergoline.Approved
SirolimusThe risk or severity of adverse effects can be increased when Cabergoline is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Cabergoline can be increased when it is combined with Sitagliptin.Approved, Investigational
SitaxentanThe risk or severity of adverse effects can be increased when Cabergoline is combined with Sitaxentan.Approved, Investigational, Withdrawn
SivelestatThe serum concentration of Cabergoline can be increased when it is combined with Sivelestat.Investigational
SolabegronCabergoline may increase the hypertensive activities of Solabegron.Investigational
SolithromycinThe serum concentration of Cabergoline can be increased when it is combined with Solithromycin.Investigational
SorafenibThe risk or severity of adverse effects can be increased when Cabergoline is combined with Sorafenib.Approved, Investigational
SotalolSotalol may increase the vasoconstricting activities of Cabergoline.Approved
SpiraprilThe serum concentration of Cabergoline can be increased when it is combined with Spirapril.Approved
St. John's WortThe serum concentration of Cabergoline can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Cabergoline can be increased when it is combined with Stiripentol.Approved
SulfamethoxazoleThe risk or severity of adverse effects can be increased when Cabergoline is combined with Sulfamethoxazole.Approved
SulfanilamideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Sulfanilamide.Approved
SulfinpyrazoneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Cabergoline can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Cabergoline.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Cabergoline is combined with Sumatriptan.Approved, Investigational
SynephrineCabergoline may increase the hypertensive activities of Synephrine.Experimental
TacrolimusThe risk or severity of adverse effects can be increased when Cabergoline is combined with Tacrolimus.Approved, Investigational
TadalafilThe risk or severity of adverse effects can be increased when Cabergoline is combined with Tadalafil.Approved, Investigational
TalinololTalinolol may increase the vasoconstricting activities of Cabergoline.Investigational
TamoxifenThe risk or severity of adverse effects can be increased when Cabergoline is combined with Tamoxifen.Approved
TapentadolThe risk or severity of adverse effects can be increased when Cabergoline is combined with Tapentadol.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Cabergoline.Approved
TelaprevirThe metabolism of Cabergoline can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Cabergoline can be decreased when combined with Telithromycin.Approved
TemocaprilThe serum concentration of Cabergoline can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Cabergoline is combined with Temsirolimus.Approved
TeniposideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Teniposide.Approved
TerbutalineCabergoline may increase the hypertensive activities of Terbutaline.Approved
TerfenadineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Terfenadine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Cabergoline.Experimental
TertatololTertatolol may increase the vasoconstricting activities of Cabergoline.Experimental
TesmilifeneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Tesmilifene.Investigational
TestosteroneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Testosterone.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Tetrahydropalmatine.Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Cabergoline is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Cabergoline is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Thioridazine.Approved, Withdrawn
ThiorphanThe serum concentration of Cabergoline can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Thiothixene.Approved
TiaprideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Tiapride.Approved, Investigational
TicagrelorThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Cabergoline can be decreased when combined with Ticlopidine.Approved
TimololTimolol may increase the vasoconstricting activities of Cabergoline.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Cabergoline is combined with Tioconazole.Approved
TipranavirThe serum concentration of Cabergoline can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineCabergoline may increase the hypertensive activities of Tizanidine.Approved
TocilizumabThe serum concentration of Cabergoline can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe risk or severity of adverse effects can be increased when Cabergoline is combined with Tofisopam.Approved
ToloxatoneThe metabolism of Cabergoline can be decreased when combined with Toloxatone.Approved
TopiroxostatThe risk or severity of adverse effects can be increased when Cabergoline is combined with Topiroxostat.Approved, Investigational
TopotecanThe risk or severity of adverse effects can be increased when Cabergoline is combined with Topotecan.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Cabergoline.Approved, Investigational
TrandolaprilThe serum concentration of Cabergoline can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe metabolism of Cabergoline can be decreased when combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Cabergoline.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Cabergoline.Approved, Investigational
TretoquinolCabergoline may increase the hypertensive activities of Tretoquinol.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Cabergoline is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Trimipramine.Approved
TroglitazoneThe risk or severity of adverse effects can be increased when Cabergoline is combined with Troglitazone.Investigational, Withdrawn
TroleandomycinThe risk or severity of adverse effects can be increased when Cabergoline is combined with Troleandomycin.Approved
TropisetronTropisetron may increase the serotonergic activities of Cabergoline.Approved, Investigational
TulobuterolCabergoline may increase the hypertensive activities of Tulobuterol.Investigational
TylosinThe serum concentration of Cabergoline can be increased when it is combined with Tylosin.Vet Approved
UbenimexThe serum concentration of Cabergoline can be increased when it is combined with Ubenimex.Experimental, Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Cabergoline.Approved, Investigational, Nutraceutical
UlinastatinThe serum concentration of Cabergoline can be increased when it is combined with Ulinastatin.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Cabergoline is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Cabergoline is combined with Veralipride.Experimental
VerapamilThe metabolism of Cabergoline can be decreased when combined with Verapamil.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Cabergoline.Approved
VildagliptinThe serum concentration of Cabergoline can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Vinblastine.Approved
VincristineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Vincristine.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe metabolism of Cabergoline can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Cabergoline.Approved
XamoterolCabergoline may increase the hypertensive activities of Xamoterol.Experimental
XimelagatranThe serum concentration of Cabergoline can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineCabergoline may increase the hypertensive activities of Xylazine.Vet Approved
YM-178Cabergoline may increase the hypertensive activities of YM-178.Investigational
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Cabergoline can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZafirlukastThe risk or severity of adverse effects can be increased when Cabergoline is combined with Zafirlukast.Approved, Investigational
ZiprasidoneThe metabolism of Cabergoline can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe serum concentration of Cabergoline can be increased when it is combined with Zofenopril.Experimental
ZolmitriptanThe risk or severity of adverse effects can be increased when Cabergoline is combined with Zolmitriptan.Approved, Investigational
ZotepineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Zotepine.Approved, Investigational
ZucapsaicinThe risk or severity of adverse effects can be increased when Cabergoline is combined with Zucapsaicin.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Cabergoline is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Absorption is not affected by food.
  • Take with food to improve tolerance.

References

Synthesis Reference
US4526892
General References
  1. Pastor P, Tolosa E: [Cabergoline in the treatment of Parkinson's disease]. Neurologia. 2003 May;18(4):202-9. [PubMed:12721865]
  2. Curran MP, Perry CM: Cabergoline : a review of its use in the treatment of Parkinson's disease. Drugs. 2004;64(18):2125-41. [PubMed:15341508]
  3. Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL: The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs. 2004;18(11):733-46. [PubMed:15330687]
  4. Miyagi M, Arai N, Taya F, Itoh F, Komatsu Y, Kojima M, Isaji M: Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents. Biol Pharm Bull. 1996 Nov;19(11):1499-502. [PubMed:8951172]
External Links
Human Metabolome Database
HMDB14393
KEGG Drug
D00987
KEGG Compound
C08187
PubChem Compound
54746
PubChem Substance
46508571
ChemSpider
49452
BindingDB
50426497
ChEBI
3286
ChEMBL
CHEMBL1201087
Therapeutic Targets Database
DAP000251
PharmGKB
PA448708
IUPHAR
37
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Cabergoline
ATC Codes
N04BC06 — CabergolineG02CB03 — Cabergoline
AHFS Codes
  • 28:36.20.04 — Ergot-derivative Dopamine Receptor Agonists

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentRecurrent Breast Cancer / Stage IV Breast Cancer1
0CompletedPreventionComplications Associated With Artificial Fertilization / Disorder of Endocrine Ovary1
1CompletedNot AvailableCocaine Abuse / Dependence, Cocaine / Substance Abuse1
1CompletedNot AvailableTo Determine Bioequivalence Under Fasting Conditions1
1CompletedOtherTo Determine Bioequivalence Under Fed Conditions1
1, 2CompletedNot AvailableBody Weights / Impaired Glucose Tolerance in Obese1
1, 2CompletedPreventionOvarian Hyperstimulation Syndrome1
2CompletedTreatmentCocaine-Related Disorders / Substance-Related Disorders1
2Not Yet RecruitingPreventionOHSS1
2RecruitingTreatmentEndometriosis1
2RecruitingTreatmentFemale Reproductive Problem1
2RecruitingTreatmentOHSS1
2, 3CompletedPreventionInfertilities2
2, 3CompletedTreatmentNon-functioning Pituitary Adenomas / Prolactinomas1
2, 3RecruitingDiagnosticInfertilities1
3Active Not RecruitingPreventionOvarian Hyperstimulation Syndrome1
3CompletedPreventionOvarian Hyperstimulation Syndrome1
3CompletedTreatmentCorticotroph Adenoma / Cushing's Disease1
3CompletedTreatmentIdiopathic Parkinson's Disease1
3CompletedTreatmentNonfunctioning Pituitary Adenoma / Pituitary Adenomas1
3CompletedTreatmentRestless Legs Syndrome (RLS)2
3RecruitingPreventionOvarian Hyperstimulation Syndrome1
3RecruitingTreatmentAcromegaly1
3RecruitingTreatmentAdenoma benign / Pituitary Neoplasms1
3RecruitingTreatmentDiabetes Mellitus (DM)1
4CompletedNot AvailableAcromegaly1
4CompletedNot AvailableProlactinomas1
4CompletedTreatmentAcromegaly2
4CompletedTreatmentAdverse Reaction to Other Drugs and Medicines1
4CompletedTreatmentParkinson's Disease (PD)1
4TerminatedTreatmentParkinson's Disease (PD)1
Not AvailableCompletedBasic ScienceOvarian Hyperstimulation Syndrome / Polycystic Ovarian Syndrome1
Not AvailableCompletedDiagnosticParkinson's Disease (PD) / Parkinsonian Syndromes1
Not AvailableUnknown StatusTreatmentMacroprolactinoma1
Not AvailableUnknown StatusTreatmentType 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
  • Impax laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Par pharmaceutical inc
  • Watson laboratories inc
  • Pharmacia and upjohn co
Packagers
Dosage forms
FormRouteStrength
TabletOral.5 mg/1
TabletOral0.5 mg
Prices
Unit descriptionCostUnit
Cabergoline 0.5 mg tablet37.39USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)102-104 °CNot Available
water solubilityInsolubleNot Available
logP2.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.064 mg/mLALOGPS
logP2.97ALOGPS
logP2.58ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)15.25ChemAxon
pKa (Strongest Basic)9.32ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area71.68 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity133.5 m3·mol-1ChemAxon
Polarizability52.5 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9383
Caco-2 permeable-0.6583
P-glycoprotein substrateSubstrate0.7972
P-glycoprotein inhibitor IInhibitor0.8903
P-glycoprotein inhibitor IIInhibitor0.7698
Renal organic cation transporterNon-inhibitor0.5339
CYP450 2C9 substrateNon-substrate0.812
CYP450 2D6 substrateNon-substrate0.7438
CYP450 3A4 substrateSubstrate0.6336
CYP450 1A2 substrateNon-inhibitor0.7733
CYP450 2C9 inhibitorNon-inhibitor0.7396
CYP450 2D6 inhibitorNon-inhibitor0.7124
CYP450 2C19 inhibitorNon-inhibitor0.8341
CYP450 3A4 inhibitorNon-inhibitor0.6476
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8712
Ames testNon AMES toxic0.5619
CarcinogenicityNon-carcinogens0.8542
BiodegradationNot ready biodegradable0.846
Rat acute toxicity2.8786 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6224
hERG inhibition (predictor II)Non-inhibitor0.5309
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as lysergic acids and derivatives. These are alkaloids with a structure based on the lysergic acid skeleton.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Ergoline and derivatives
Sub Class
Lysergic acids and derivatives
Direct Parent
Lysergic acids and derivatives
Alternative Parents
Indoloquinolines / Benzoquinolines / Pyrroloquinolines / Quinoline-3-carboxamides / 3-alkylindoles / Piperidinecarboxamides / Isoindoles and derivatives / N-acyl ureas / Aralkylamines / Benzenoids
show 10 more
Substituents
Lysergic acid or derivatives / Indoloquinoline / Benzoquinoline / Quinoline-3-carboxamide / Pyrroloquinoline / Quinoline / 3-alkylindole / Indole / Indole or derivatives / Isoindole or derivatives
show 28 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-acylurea (CHEBI:3286)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Lombardi G, Varsaldi F, Miglio G, Papini MG, Battaglia A, Canonico PL: Cabergoline prevents necrotic neuronal death in an in vitro model of oxidative stress. Eur J Pharmacol. 2002 Dec 20;457(2-3):95-8. [PubMed:12464354]
  3. Kageyama K, Nigawara T, Kamata Y, Takahashi T, Anzai J, Suzuki S, Osamura YR, Suda T: A case of macroprolactinoma with subclinical growth hormone production. Endocr J. 2002 Feb;49(1):41-7. [PubMed:12008749]
  4. Pastor P, Tolosa E: [Cabergoline in the treatment of Parkinson's disease]. Neurologia. 2003 May;18(4):202-9. [PubMed:12721865]
  5. Curran MP, Perry CM: Cabergoline : a review of its use in the treatment of Parkinson's disease. Drugs. 2004;64(18):2125-41. [PubMed:15341508]
  6. Miyagi M, Arai N, Taya F, Itoh F, Komatsu Y, Kojima M, Isaji M: Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents. Biol Pharm Bull. 1996 Nov;19(11):1499-502. [PubMed:8951172]
  7. Ichikawa K, Kojima M: [Pharmacological effects of cabergoline against parkinsonism]. Nihon Yakurigaku Zasshi. 2001 Jun;117(6):395-400. [PubMed:11436517]
  8. Linazasoro G: Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease. Clin Neuropharmacol. 2008 Jan-Feb;31(1):19-24. doi: 10.1097/wnf.0b013e318067bcc4. [PubMed:18303487]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation...
Gene Name
HTR2B
Uniprot ID
P41595
Uniprot Name
5-hydroxytryptamine receptor 2B
Molecular Weight
54297.41 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
  3. Sharif NA: Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action. Curr Drug Targets. 2010 Aug;11(8):978-93. [PubMed:20426763]
  4. Sharif NA, McLaughlin MA, Kelly CR, Katoli P, Drace C, Husain S, Crosson C, Toris C, Zhan GL, Camras C: Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. Exp Eye Res. 2009 Mar;88(3):386-97. doi: 10.1016/j.exer.2008.10.003. Epub 2008 Nov 1. [PubMed:18992242]
  5. Huang XP, Setola V, Yadav PN, Allen JA, Rogan SC, Hanson BJ, Revankar C, Robers M, Doucette C, Roth BL: Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. Mol Pharmacol. 2009 Oct;76(4):710-22. doi: 10.1124/mol.109.058057. Epub 2009 Jul 1. [PubMed:19570945]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
  3. Sharif NA, McLaughlin MA, Kelly CR, Katoli P, Drace C, Husain S, Crosson C, Toris C, Zhan GL, Camras C: Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. Exp Eye Res. 2009 Mar;88(3):386-97. doi: 10.1016/j.exer.2008.10.003. Epub 2008 Nov 1. [PubMed:18992242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
  3. Sharif NA: Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action. Curr Drug Targets. 2010 Aug;11(8):978-93. [PubMed:20426763]
  4. Sharif NA, McLaughlin MA, Kelly CR, Katoli P, Drace C, Husain S, Crosson C, Toris C, Zhan GL, Camras C: Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. Exp Eye Res. 2009 Mar;88(3):386-97. doi: 10.1016/j.exer.2008.10.003. Epub 2008 Nov 1. [PubMed:18992242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
  3. Sharif NA, McLaughlin MA, Kelly CR, Katoli P, Drace C, Husain S, Crosson C, Toris C, Zhan GL, Camras C: Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. Exp Eye Res. 2009 Mar;88(3):386-97. doi: 10.1016/j.exer.2008.10.003. Epub 2008 Nov 1. [PubMed:18992242]
  4. Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther. 2002 Nov;303(2):805-14. [PubMed:12388667]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1D
Uniprot ID
P28221
Uniprot Name
5-hydroxytryptamine receptor 1D
Molecular Weight
41906.38 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther. 2002 Nov;303(2):805-14. [PubMed:12388667]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
  3. Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther. 2002 Nov;303(2):805-14. [PubMed:12388667]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
  3. Sharif NA, McLaughlin MA, Kelly CR, Katoli P, Drace C, Husain S, Crosson C, Toris C, Zhan GL, Camras C: Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. Exp Eye Res. 2009 Mar;88(3):386-97. doi: 10.1016/j.exer.2008.10.003. Epub 2008 Nov 1. [PubMed:18992242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
  3. Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther. 2002 Nov;303(2):805-14. [PubMed:12388667]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD5
Uniprot ID
P21918
Uniprot Name
D(1B) dopamine receptor
Molecular Weight
52950.5 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Kvernmo T, Hartter S, Burger E: A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther. 2006 Aug;28(8):1065-78. [PubMed:16982285]
  3. Ichikawa K, Kojima M: [Pharmacological effects of cabergoline against parkinsonism]. Nihon Yakurigaku Zasshi. 2001 Jun;117(6):395-400. [PubMed:11436517]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
  3. Kvernmo T, Hartter S, Burger E: A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther. 2006 Aug;28(8):1065-78. [PubMed:16982285]
  4. Ichikawa K, Kojima M: [Pharmacological effects of cabergoline against parkinsonism]. Nihon Yakurigaku Zasshi. 2001 Jun;117(6):395-400. [PubMed:11436517]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1B
Uniprot ID
P28222
Uniprot Name
5-hydroxytryptamine receptor 1B
Molecular Weight
43567.535 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
  3. Sharif NA: Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action. Curr Drug Targets. 2010 Aug;11(8):978-93. [PubMed:20426763]
  4. Sharif NA, McLaughlin MA, Kelly CR, Katoli P, Drace C, Husain S, Crosson C, Toris C, Zhan GL, Camras C: Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. Exp Eye Res. 2009 Mar;88(3):386-97. doi: 10.1016/j.exer.2008.10.003. Epub 2008 Nov 1. [PubMed:18992242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR7
Uniprot ID
P34969
Uniprot Name
5-hydroxytryptamine receptor 7
Molecular Weight
53554.43 Da
References
  1. Sharif NA, McLaughlin MA, Kelly CR, Katoli P, Drace C, Husain S, Crosson C, Toris C, Zhan GL, Camras C: Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. Exp Eye Res. 2009 Mar;88(3):386-97. doi: 10.1016/j.exer.2008.10.003. Epub 2008 Nov 1. [PubMed:18992242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804. [PubMed:12388666]
  2. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804. [PubMed:12388666]
  2. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804. [PubMed:12388666]
  2. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804. [PubMed:12388666]
  2. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804. [PubMed:12388666]
  2. PDSP Ki Database [Link]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.

Components:
References
  1. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804. [PubMed:12388666]
  2. PDSP Ki Database [Link]
22. D(2S) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
References
  1. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804. [PubMed:12388666]
  2. PDSP Ki Database [Link]
23. D(2L) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
References
  1. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804. [PubMed:12388666]
  2. PDSP Ki Database [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18